Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus SOX versus SOX for conversion treatment of advanced gastric cancer
ChiCTR1900023924Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib, tegafur + gimeracil + oteracil and oxaliplatin in gastric cancer (GC) and gastric adenocarcinoma (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Radical resection rate after conversion therapy. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
Rivoceranibtegafur + gimeracil + oteraciloxaliplatin
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900023924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023924.